Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Nedaplatin with Radiotherapy for Esophageal SCC
NCT02964455Phase 1Completed
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2016
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of docetaxel and nedaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Primary endpoints: Occurrence of dose limiting toxicity at 8.5 weeks and Maximum tolerated dose at 8.5 weeks. Started Nov 2016; status: completed.
02
Drugs
docetaxelnedaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02964455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964455.